SI-BONE Business Summary

SI-BONE, Inc. (SIBN) is a leading medical technology company that generates revenue through the development and sale of proprietary titanium implant systems for sacroiliac (SI) joint fusion, adult spinal deformity, and pelvic trauma. Its primary revenue model is transactional, driven by the sale of its iFuse Implant System—including the 3D-printed iFuse-3D and the iFuse-TORQ threaded implants—to hospitals and ambulatory surgery centers (ASCs). The company’s business is segmented into U.S. operations, which account for approximately 95% of total revenue, and international markets. SI-BONE is the undisputed category leader in the minimally invasive SI joint fusion market, distinguished as the only provider with a PMA-cleared implant system and a clinical evidence base exceeding 200 peer-reviewed publications. It competes directly with diversified spine giants such as Medtronic and Globus Medical, as well as specialized players like PainTEQ and Nevro, maintaining its market-leading position through a specialized direct sales force and superior payer coverage. Founded in 2008 by Dr. Mark Reiley, a renowned orthopedic surgeon and the founder of Kyphon, SI-BONE is currently led by CEO Laura A. Francis, who previously served as the company’s CFO and COO and was instrumental in its 2018 IPO. The executive leadership team includes Anshul Maheshwari as CFO, Scott Yerby, PhD, as SVP of Engineering and CTO, and Anthony Recupero as President of Commercial Operations, all of whom bring extensive experience from leading medical device firms like Varian Medical Systems and Kyphon. The company is supported by a robust board chaired by Executive Chairman Jeff Dunn and maintains significant institutional backing from investors such as Arboretum Ventures, Champlain Investment Partners, and Impax Asset Management. This leadership pedigree combines deep biomechanical engineering expertise with a proven track record in commercial scaling to drive the company toward its 2026 goals of positive adjusted EBITDA and free cash flow.